Your browser doesn't support javascript.
Circulating proteins to predict COVID-19 severity.
Su, Chen-Yang; Zhou, Sirui; Gonzalez-Kozlova, Edgar; Butler-Laporte, Guillaume; Brunet-Ratnasingham, Elsa; Nakanishi, Tomoko; Jeon, Wonseok; Morrison, David R; Laurent, Laetitia; Afilalo, Jonathan; Afilalo, Marc; Henry, Danielle; Chen, Yiheng; Carrasco-Zanini, Julia; Farjoun, Yossi; Pietzner, Maik; Kimchi, Nofar; Afrasiabi, Zaman; Rezk, Nardin; Bouab, Meriem; Petitjean, Louis; Guzman, Charlotte; Xue, Xiaoqing; Tselios, Chris; Vulesevic, Branka; Adeleye, Olumide; Abdullah, Tala; Almamlouk, Noor; Moussa, Yara; DeLuca, Chantal; Duggan, Naomi; Schurr, Erwin; Brassard, Nathalie; Durand, Madeleine; Del Valle, Diane Marie; Thompson, Ryan; Cedillo, Mario A; Schadt, Eric; Nie, Kai; Simons, Nicole W; Mouskas, Konstantinos; Zaki, Nicolas; Patel, Manishkumar; Xie, Hui; Harris, Jocelyn; Marvin, Robert; Cheng, Esther; Tuballes, Kevin; Argueta, Kimberly; Scott, Ieisha.
  • Su CY; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Zhou S; Department of Computer Science, McGill University, Montréal, QC, Canada.
  • Gonzalez-Kozlova E; Quantitative Life Sciences Program, McGill University, Montreal, Quebec, Canada.
  • Butler-Laporte G; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Brunet-Ratnasingham E; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
  • Nakanishi T; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Jeon W; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Morrison DR; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
  • Laurent L; Research Centre of the Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada.
  • Afilalo J; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Afilalo M; Department of Human Genetics, McGill University, Montreal, QC, Canada.
  • Henry D; Graduate School of Medicine, McGill International Collaborative School in Genomic Medicine, Kyoto University, Kyoto, Japan.
  • Chen Y; Japan Society for the Promotion of Science, Tokyo, Japan.
  • Carrasco-Zanini J; Department of Computer Science, McGill University, Montréal, QC, Canada.
  • Farjoun Y; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Pietzner M; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Kimchi N; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Afrasiabi Z; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
  • Rezk N; Department of Emergency Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada.
  • Bouab M; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Petitjean L; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Guzman C; Department of Human Genetics, McGill University, Montreal, QC, Canada.
  • Xue X; MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  • Tselios C; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Vulesevic B; MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  • Adeleye O; Computational Medicine, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Abdullah T; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Almamlouk N; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Moussa Y; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • DeLuca C; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Duggan N; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Schurr E; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Brassard N; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Durand M; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Del Valle DM; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Thompson R; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Cedillo MA; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Schadt E; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Nie K; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Simons NW; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Mouskas K; Lady Davis Institute for Medical Research, Jewish General Hospital, Pavilion H-413, 3755 Côte-Ste-Catherine Montréal, Montreal, QC, H3T 1E2, Canada.
  • Zaki N; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • Patel M; Research Centre of the Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada.
  • Xie H; Research Centre of the Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada.
  • Harris J; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Marvin R; Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Cheng E; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tuballes K; Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Argueta K; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Scott I; Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sci Rep ; 13(1): 6236, 2023 04 17.
Article in English | MEDLINE | ID: covidwho-2304268
ABSTRACT
Predicting COVID-19 severity is difficult, and the biological pathways involved are not fully understood. To approach this problem, we measured 4701 circulating human protein abundances in two independent cohorts totaling 986 individuals. We then trained prediction models including protein abundances and clinical risk factors to predict COVID-19 severity in 417 subjects and tested these models in a separate cohort of 569 individuals. For severe COVID-19, a baseline model including age and sex provided an area under the receiver operator curve (AUC) of 65% in the test cohort. Selecting 92 proteins from the 4701 unique protein abundances improved the AUC to 88% in the training cohort, which remained relatively stable in the testing cohort at 86%, suggesting good generalizability. Proteins selected from different COVID-19 severity were enriched for cytokine and cytokine receptors, but more than half of the enriched pathways were not immune-related. Taken together, these findings suggest that circulating proteins measured at early stages of disease progression are reasonably accurate predictors of COVID-19 severity. Further research is needed to understand how to incorporate protein measurement into clinical care.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Sci Rep Year: 2023 Document Type: Article Affiliation country: S41598-023-31850-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Sci Rep Year: 2023 Document Type: Article Affiliation country: S41598-023-31850-y